Researchers from the University of Copenhagen have discovered a new weight loss drug target that works without causing nausea ...

Researchers at the University of Copenhagen have identified a promising new drug target for weight loss which could revolutionise treatment for millions of people with obesity and type 2 diabetes. The ...

Stopping semaglutide, marketed as Wegovy and Ozempic, which helps people lose weight , can have severe health impacts, a new ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

An update from Vivani Medical ( (VANI) ) is now available. Vivani Medical is advancing its innovative GLP-1 implant technology to address ...

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Preliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity ...